ABBVIE CARE TERMS & CONDITIONS AND PRIVACY STATEMENT

TERMS AND CONDITIONS

  1. Only Australian residents who have been prescribed HUMIRA (adalimumab) by their healthcare practitioner are eligible to enrol in and continue their participation in AbbVie Care (the “Program”).
  2. If enrolment is for a patient prescribed HUMIRA for a paediatric indication, and the patient is under 18 years of age, as the legal parent/carer/guardian you give consent for them to be enrolled into the AbbVie Care program
  3. The Program is sponsored by AbbVie Pty Ltd (ABN 48 156 384 262) (“AbbVie”) and managed and administered by AbbVie’s authorised nominated third party provider(“Nominated Third Party”). Nominated Third Party will facilitate the provision of communications, including all phone calls, mail, emails and SMS for the Program.
  4. The Program offers a range of health, wellness and treatment logistics services (further detail on each is outlined below). Involvement in the Program is designed to complement and support the prescribing instructions of your healthcare practitioner who is responsible for prescribing HUMIRA for your medical condition (your “Prescribing Specialist”).
  5. The program does not replace the advice of your Prescribing Specialist or other healthcare professionals. You should speak to your Prescribing Specialist if you have any questions or concerns about your treatment. You should also refer to the Humira Consumer Medicines Information available at www.medicines.org.au or by calling Medical Information on 1800 043 460 if you have any further questions or concerns.
  6. The duration of your enrolment in the Program will be dependent upon your continued treatment with HUMIRA, the services of the Program you elect to participate in and/or any specific requests from your Prescribing Specialist.
  7. You may be sent SMS messages that you can reply to with, “STOP” for Unsubscribe. It is important to note that your response is limited to four (4) characters in length. Any message over 4 characters is unable to be read or reviewed by our SMS gateway. If you wish to provide additional feedback please contact us by calling 1800 486 472 or writing to the AbbVie Care team at AbbVie Care, Reply Paid 86675, PO Box 6042, North Sydney NSW 2059 (no stamp required).
  8. You may opt out of any part of this Program (e.g. phone calls, mail, SMS, emails and/or other communications) or the whole Program at any time by calling 1800 486 472 or writing to: AbbVie Care Team at AbbVie Care, Reply Paid 86675, PO Box 6042, North Sydney NSW 2059 (no stamp required), reply “STOP” to SMS or fax to 1800 219 836. If you opt out of this Program, we may still need to hold the information collected from you as part of the Program for purposes permitted by law including reporting purposes. To the extent we retain any personal information it will be handled in accordance with the Program Privacy Policy.
  9. AbbVie reserves the right to cease funding the Program and/or terminate the Program with reasonable notice at any time.
  10. AbbVie reserves the right to change and/or cease providing any of the services within the Program with reasonable notice at any time.

Services

  1. The Program offers the following services:

AbbVie Care Support Services

    1. Injection Training - involves training on appropriate injection technique (with the HUMIRA Syringe or Pen). Following your enrolment into injection training, your record of enrolment will be provided to a third party nursing services agency who will contact you to arrange the training. An additional visit by the third party nursing services agency may be arranged at your request or the request of your Prescribing Specialist by contacting Nominated Third Party on 1800 486 472.
    2. Health Coaching Support Services - involves a combination of over the phone and email health coaching support services from Nominated Third Party. Following your enrolment into health coaching support services, a health coach from Nominated Third Party will contact you to arrange these services. As part of this service, you will be offered up to five (5) telephone calls, aimed at identifying a health goal you wish to work towards, follow up telephone calls to determine your progress and any further actions. The health coach may also provide you with information for additional third party support services.
    3. General Health and Wellness Information and Support Services - consists of email and/or telephone health and wellness support services. You will receive regular communications (via email, SMS or mail) covering a range of educational topics, reminders about a number of optional Program offerings (e.g. a sharps container and travel bag delivery service) and surveys at various time points to ask you how you are finding the Program.
    4. Reminder Services - consists of SMS and/or email reminder services regarding the timing of your medication, the collection of your prescription, and appointments with your Prescribing Specialist. The Reminder Services provided by the Program are to assist you with the usual medication reminder methods that you have adopted for the timing of your medication, the collection of your prescription, and appointments with your Prescribing Specialist, and you should not rely solely on this service to remind you of these actions required.
    5. Program Website – you will be provided access to a comprehensive range of online support services and also management tips, support tools and information relating to HUMIRA available on “www.abbviecare.com.au” (“Website”) following your enrolment into the Program.

All of the services offered as part of the AbbVie Care Support Services are optional allowing you to opt into all or just a selection of the services provided.

  1. Medication Management Services - which consists of:
  1. Getting Started , which are a series of communications (phone, email and/ or SMS) provided by the Program regarding whether you have received your prescription, guidance on the next steps of the logistics of your treatment journey, and preparing for your next pharmacy visit;
  2. Staying on track , which includes communications (phone, email and/or SMS) provided by the Program at key times to assist with managing your appointment schedule (including with your Prescribing Specialist and appointments for your pathology tests). The Staying on Track communications provided by the Program are to assist you with the usual reminder methods that you have adopted for managing your appointment schedules, and you should not rely solely on this service to remind you of these actions required;
  3. Continuing Treatment , which includes communications (phone, email and/or SMS) provided by the Program on appointment scheduling and reminders for your pathology test appointments and consultations with your Prescribing Specialist. The Continuing Treatment communications provided by the Program are to assist you with the usual reminder methods that you have adopted for managing your appointment scheduling and reminders for your pathology test appointments and consultations with your Prescribing Specialist, and you should not rely solely on this service to remind you of these actions required.
  4. Pharmacy Liaison Services , which includes email or SMS reminder services provided by the Program and regular contact with your Pharmacist to confirm your prescription is filled at the right times. The Pharmacy Liaison Services provided by the Program are to assist you with the usual reminder methods that you have adopted for confirming that your prescription is filled at the right times, and you should not rely solely on this service to remind you of these actions required.

If you opt into the Medication Management Services, you will receive all of the services listed above.

  1. As part of your participation in the Medication Management Services, in order to provide you the associated Pharmacy Liaison Services component, you must nominate a pharmacy where you propose to fill your prescription. You are also required to provide your consent for Nominated Third Party to provide your name and contact information to your nominated pharmacy to enable Nominated Third Party to correctly identify you. Following your enrolment, Nominated Third Party will phone your nominated pharmacy and confirm your pharmacy ID number with their primary pharmacist (“Pharmacist”). The purpose of this process is to ensure the Pharmacist receives an outline of the Program and confirmation of your enrolment in the Program. This also allows Nominated Third Party to provide the Pharmacy Liaison Services which include:
  1. confirming your prescription status each month; and
  2. providing the reminder services as part of the Program.

These reminder services provided by the Program are to assist you with the usual reminder methods that you have adopted, and you should not rely solely on this service to remind you of these actions required.

If you have been referred to the Program by your Prescribing Specialist, information captured within the Pharmacy Liaison Service is shared with your Prescribing Specialist to assist them with managing your treatment with Humira (adalimumab).

How to Enrol into the Program

  1. Enrolment into the Program is either by:
  1. self-enrolment – you can enrol yourself in any of the services in the Program via www.abbviecare.com.au, by phoning 1800 486 472, sending a fax to 1800 219 863 or emailing support@abbviecare.com.au; or
  2. your Prescribing Specialist’s referral (discussed further below)
  3. your Pharmacist’s referral (discussed further below).

Program Mandatories

In order to opt into any/all of the available Program services, you must acknowledge that you have understood and agreed to the following:

  • Terms and Conditions & Privacy Statement; these may be provided by any of the following methods:
    • Your Prescribing Specialist
    • Your Pharmacist
    • Via www.abbviecare.com.au at time of enrolment
    • Nominated Third Party at time of enrolment.
  1. If you are referred by your Prescribing Specialist, they have provided your contact information (email address and/or phone number) to Nominated Third Party, who will contact you to complete your enrolment. They will receive an update about your progress from Nominated Third Party via the Program’s Prescribing Specialist Portal (“Portal”). The Portal is a secure password protected section of www.abbviecare.com.au that is only available to your Prescribing Specialist, the Prescribing Specialist’s additional users nominated by your Prescribing Specialist (e.g. clinic nurses, clinic administrators or other authorised personnel) (“Nominated Users”), Nominated Third Party and nominated parties providing information technology services. If you opt out of this Program, your prescribing specialist may still need to hold the information collected from you as part of the Program for purposes permitted by law including reporting purposes. To the extent we retain any personal information it will be handled in accordance with the Program Privacy Policy.
  2. If you are referred by your Pharmacist, they have provided your contact information (email address and/or phone number) to Nominated Third Party, who will contact you to complete your enrolment. Your Pharmacist will receive AUD$10.00 from AbbVie as a result of referring you to the Program.


PRIVACY STATEMENT

AbbVie Pty Ltd’s authorised nominated third party provider (“Nominated Third Party”) will collect, use, store and/or disclose personal information relating to you in connection with AbbVie Care (“the Program”), for purposes of administering your involvement in the Program, or to assess your interest in participating in market research or AbbVie sponsored research projects related to the Program. Nominated Third Party uses your personal information primarily to manage your participation in the Program and for other purposes as notified to you. Nominated Third Party may share your personal information with selected third party service providers (who may be located outside of Australia) in accordance with the Program Privacy Policy. Nominated Third Party will not use your personal information for any other purposes unless Nominated Third Party has your consent to do so or is required to do so by law. If you do not provide personal information when requested, Nominated Third Party will not be able to manage your participation in the Program and, as a result, you may not be able to participate. Nominated Third Party takes reasonable steps to protect such personal information from misuse, interference, loss and unauthorised access, modification or disclosure. Your personal information will be handled in accordance with the Program Privacy Policy which details (amongst other things) how you can access, correct or complain about the handling of your personal information, and how Nominated Third Party will respond to your requests or complaints. If you have any questions or if you would like a copy of the Program Privacy Policy, or if you would like to see or correct your records or if you have any queries or complaints, please contact Nominated Third Party at any time by calling 02 8373 7400 or writing to the AbbVie Care team at AbbVie Care, Reply Paid 86675, PO Box 6042, North Sydney NSW 2059 (no stamp required) or fax to 1800 219 836.

Before you submit any information and agree to enrol in the Program, you should be aware of and consent to the following:

FOR PATIENTS

Consent: By providing your personal information (including your name, age, contact details; as well as, sensitive information relating to your medical condition being treated with HUMIRA (adalimumab)), you consent to AbbVie Pty Ltd’s (“AbbVie”) authorised nominated third party provider (“Nominated Third Party”) contacting you, collecting and using your personal information in accordance with the Program Terms and Conditions and the Program Privacy Policy in connection with the administration and management of the Program, or to assess your interest in participating in market research or AbbVie sponsored research projects related to the Program.

Collection and Use of Your Personal Information: Nominated Third Party will collect personal information directly from you and your nominated pharmacist (“Pharmacist”). If you have been referred to the Program by the healthcare practitioner who is responsible for prescribing HUMIRA (adalimumab) for your medical condition (“your Prescribing Specialist”), your personal information will be stored in a Program database which is accessible by your Prescribing Specialist and additional users nominated by your Prescribing Specialist (eg clinic nurses, clinic administrators or other authorised personnel) (“Nominated Users”) in accordance with the Program Terms and Conditions and the Program Privacy Policy. Nominated Third Party may also disclose your personal information to other persons involved with the Program, such as third party service providers, in accordance with the Program Terms and Conditions and the Program Privacy Policy. Nominated Third Party may use your personal information to contact you as necessary to clarify certain aspects of your personal information and/or to review your experience/participation in the Program, and to assess your interest in participating in market research or AbbVie sponsored research projects related to the Program.

Data Sharing With AbbVie: Any self-reported safety events (including adverse events, special situations and product complaints) that arise from taking HUMIRA (adalimumab) will be reported to AbbVie for the purpose of reporting this information to the appropriate regulatory notification body and/or in accordance with AbbVie’s Safety Information reporting processes. AbbVie may also use the personal information to contact you to obtain additional information relating to your safety event (including adverse events, special situations and product complaints). AbbVie may also have access for information technology services purposes for system administration only. Otherwise, de-identified information relating to your participation in the Program, such as information about your prescription collection status, and PBS treatment eligibility assessment criteria will be collated into a report for AbbVie. AbbVie may use this information for internal purposes, including planning and managing resources for the Program, and analysis and research purposes (e.g. to calculate patient adherence rates). AbbVie may disclose the information to other third parties in order to promote awareness of the Program and to publish the information in reports or medical publications. You will not be able to be identified in any form of report or publication. Any personal information collected by AbbVie will be handled in accordance with AbbVie’s privacy policy available at www.abbvie.com.au/privacy/home.html.

FOR PRESCRIBING SPECIALISTS AND HEALTHCARE PROFESSIONALS

Consent: In completing your enrolment to participate in the Program, you consent to AbbVie Pty Ltd’s (“AbbVie”) authorised nominated third party provider (“Nominated Third Party”), collecting and using the personal information you provide regarding yourself (e.g. name and contact details) to contact you in relation to the Program, including patient-related updates, and otherwise as necessary to undertake the Program.

Collection and Use of Your Personal Information: Nominated Third Party may collect your personal information directly from you or may source such information from AbbVie’s use of third party databases (e.g. OneKey) to complete your registration details for the Program. If you are an additional user nominated by a Prescribing Specialist (eg clinic nurses, clinic administrators or other authorised personnel) (“Nominated User”), Nominated Third Party may collect basic personal information from the Prescribing Specialist who has nominated you to administer their patients’ participation in the Program. Personal information we hold about you will be linked to the patients who you have enrolled in the Program. Your personal information will be used for the purposes of administering the Program, including but not limited to adverse event reporting, and may be disclosed to other third parties involved in the delivery of the Program (e.g. pharmacists).

Prescribing Specialist Portal (“Portal”): The Portal can only be accessed by secure login upon registration, and is held within www.abbviecare.com. au. Prescribing Specialists are designated a master account (“Master Account”), which provides access to:

  1. an online tool that allows Prescribing Specialists and their Nominated Users to refer patients for enrolment in the Program;
  2. a Patient Progress Dashboard, which sets out the status of all a Prescribing Specialist’s patients linked to their Master Account including any post injection reports from the nurse training, their patient’s initial prescription date, each of their patient’s prescription collection status (should such information be provided to Nominated Third Party), pathology and Prescribing Specialist appointment confirmations and other information relevant to assist in preparation for their patient’s reassessment appointment. The Patient Progress Dashboard is provided to assist you with the methods that you have adopted for managing your patients and you should not rely solely on this for managing your patients, and
  3. additional information, including but not limited to, HUMIRA (adalimumab) Product Information, PBS Information, Minimum Product Information, Consumer Medical Information, the Program Terms and Conditions and the Program Privacy Policy

During the registration process, Nominated Third Party will offer the Prescribing Specialist the opportunity to nominate Nominated Users to access their Master Account. The Prescribing Specialist confirms that the Nominated User is authorised to be linked to the Prescribing Specialist’s Master Account. The Prescribing Specialist will provide any reasonable assistance requested from Nominated Third Party in order for Nominated Third Party to obtain any consents necessary to contact the Prescribing Specialist’s Nominated User(s).

The name of a Prescribing Specialist and his/her Nominated Users, their contact details, total number of patient enrolments, and channel of enrolment will be collated into a report for AbbVie. Patient specific information will not be included in any report provided to AbbVie. AbbVie may use this information for internal purposes, including planning and managing resources for the Program, and analysis and research purposes (e.g. to calculate patient adherence rates). AbbVie may disclose the information to third parties in order to promote awareness of the Program and to publish the information in reports or medical publications. The name of the Prescribing Specialist and his/her Nominated Users will not be able to be identified in any form of report or publication. Any personal information collected by AbbVie will be handled in accordance with AbbVie’s privacy policy available at www.abbvie.com.au/ privacy/home.html .

Personal Data of Patients:

If you are a Prescribing Specialist or Nominated User, you confirm that you are authorised to collect your patient’s personal information (including email address and phone number), and have provided the necessary notifications to each patient (or their guardian) you are nominating for enrolment into the Program. You confirm that you have informed your patient that Nominated Third Party will contact them to complete their enrolment into the Program, in accordance with the Program Terms and Conditions and Program Privacy Policy.

How to Contact Us

If you have any questions in relation to privacy, please contact us on 02 8373 7400, or by writing to the AbbVie Care team at support@abbviecare. com.au or AbbVie Care, Reply Paid 86675, PO Box 6042, North Sydney NSW 2059 (no stamp required) or fax to 1800 219 836.

AbbVie & AbbVie Care are registered trademarks of AbbVie Inc. AbbVie Pty Ltd. ABN 48 156 384 262. Mascot NSW 2020 Australia. CLA-AU-180016 August 2018

Copyright© 2016 AbbVie Pty Ltd. MASCOT, NSW 2020. Australia AU-HUMO-2013-31(3) September 2016